EUVIMEDObjevte EUVIMED
Crossref

High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis

Ryoong-Jin Oh, Yasuo Yoshioka, Eiichi Tanaka, Hiroya Shiomi, Iori Sumida, Fumiaki Isohashi, Osamu Suzuki, Koji Konishi, Yoshifumi Kawaguchi, Satoaki Nakamura, Masahiro Kato, Takehiro Inoue

Radiation Medicine · 2006

DOI: 10.1007/bf02489990 ↗

At a glance

Journal article in Radiation Medicine, 2006. Written by Ryoong-Jin Oh and 11 co-authors. Institution: Department of Radiation Oncology, Osaka University Graduate School of Medicine, Japan. Cited 5 times so far (Crossref); 32 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

PURPOSE: High-dose-rate (HDR) brachytherapy combined with hormonal therapy (HTx), without the addition of external beam radiation therapy (EBRT) for high-risk prostate cancer was evaluated retrospectively. MATERIALS AND METHODS: Between May 1995 and April 2002, 35 patients with prostate cancer [Stage > or = T2b (UICC 1997) or tumor grading=3 or prostate-specific antigen (PSA) level > or = 20 ng/mL] were treated with HDR brachytherapy combined with HTx. Most patients (74%) had two or more of these factors. All patients received Iridium-192 HDR brachytherapy with a total dose of 54 Gy/9 fractions/5 days (48 Gy/8 fractions/5 days for the first 6 cases) in one implant session. The median neoadjuvant HTx [luteinizing hormone-releasing hormone (LH-RH) agonist and antiandrogen] period was 7 months. The median adjuvant HTx (ATH) (LH-RH agonist) period was 40 months, and median follow-up was 57 months (range, 23-117 months). RESULTS: The 5-year actuarial biochemical control, local control, and disease-free rates were 62%, 96%, and 76% respectively. No patients experienced local and/or regional relapse without distant progression. The 5-year actuarial cause-specific survival and overall survival rates were 89% and 87%, respectively. The acute and late toxicity were moderate and well tolerated. CONCLUSION: HDR brachytherapy plus long-term HTx is at least as effective as conventional EBRT plus long-term HTx.

Subjects

MeSH terms (MEDLINE)

AgedAged, 80 and overAndrogen AntagonistsBrachytherapyCombined Modality TherapyDose Fractionation, RadiationGonadotropin-Releasing HormoneHumansIridium RadioisotopesMaleMiddle AgedNeoplasm StagingProstatic NeoplasmsRetrospective StudiesSurvival RateTreatment Outcome

Substances

Androgen AntagonistsIridium RadioisotopesGonadotropin-Releasing Hormone

Authors and institutions

  • Department of Radiation Oncology, Osaka University Graduate School of Medicine, Japan.

Cite

APA

Oh, R. J., Yoshioka, Y., Tanaka, E., Shiomi, H., Sumida, I., Isohashi, F., Suzuki, O., Konishi, K., Kawaguchi, Y., Nakamura, S., Kato, M., & Inoue, T. (2006). High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis. Radiation Medicine. https://doi.org/10.1007/bf02489990

Vancouver

Oh RJ, Yoshioka Y, Tanaka E, Shiomi H, Sumida I, Isohashi F, et al. High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis. Radiation Medicine. 2006. doi:10.1007/bf02489990

BibTeX
@article{Oh2006,
  author = {Oh, Ryoong-Jin and Yoshioka, Yasuo and Tanaka, Eiichi and Shiomi, Hiroya and Sumida, Iori and Isohashi, Fumiaki and Suzuki, Osamu and Konishi, Koji and Kawaguchi, Yoshifumi and Nakamura, Satoaki and Kato, Masahiro and Inoue, Takehiro},
  title = {High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: Results of a retrospective analysis},
  journal = {Radiation Medicine},
  year = {2006},
  doi = {10.1007/bf02489990}
}
Start for free →